

1996

Personal Statement:

As an abdominal transplant surgeon I have over 25 years of clinical experience in solid organ transplantation and complex hepato-biliary surgery. I am multi-organ trained (University of Nebraska Medical Center) with a personal experience of over 2,000 liver transplants including pediatric and split liver transplantation. My career has allowed me to build and lead abdominal transplant teams twice (adult liver/pediatric kidney and liver, abdominal multi-organ). Each time the program was able to achieve outcomes among the best in the country based on risk adjusted patient/graft survival, rates of transplant and survival on waiting list. The current program I lead (Memorial Hermann TMC/McGovern School of Medicine University of Texas Houston) is in the top 10 for one-year survival post-transplant with one of the lowest mortality of waiting list and highest rate of transplantation for the country – SRTR data 01/2020. The kidney transplant program at Memorial Hermann TMC also performs well above expected with one of the best 3 year graft survival as well as the shortest waiting time to transplantation in the state of Texas, SRTR data release 01/2020. In 2019, the kidney transplant program was recognized by UNOS thru the COIIN project (Collaborative Improvement and Innovation Network – (designed to look at best practices to increase the utilization of cadaver kidneys and increase the number of patients transplanted). Each program I have lead is centered on the patient experience by achieving optimal outcomes with respect for the patient and their family. The goal I have always emphasized, to the patient care team, is to become the leader (content expert) in patient care in our area of expertise (abdominal transplantation), setting the standards that other providers seek to emulate and patients wish to have provide their care.

Curriculum Vitae

September 1, 2019
Page 2 of 28

NAME: John Stevenson (Steve) Bynon Jr., M.D., FACS

PRESENT TITLE: Professor of Surgery and Director
Division of Immunology and Organ Transplantation

WORK ADDRESS: 6411 Fannin Street, Jones 1-400
Houston, TX 77030

BIRTHDATE: October 13, 1959

CITIZENSHIP: United States of America

UNDERGRADUATE EDUCATION:

1981 University of Tennessee (B.A./Honors in Biology)

GRADUATE EDUCATION:

1985 University of Tennessee Center for the Health Sciences (M.D.)

POSTGRADUATE TRAINING:

1985-1989 Resident in General Surgery
University of Alabama at Birmingham, University of Alabama Hospital

1989-1990 Chief Resident in General Surgery
University of Alabama at Birmingham, University of Alabama Hospital

1991-1993 Fellowship in Transplantation Surgery
University of Nebraska College of Medicine, University of Nebraska
Medical Center, Omaha

ACADEMIC APPOINTMENTS:

1993-2001 Assistant Professor of Surgery

2002-2011 Associate Professor of Surgery with Tenure
Division of Transplantation
University of Alabama School of Medicine

2005-2011 Arnold G. Diethelm Endowed Chair of Transplantation
Division of Transplantation
University of Alabama School of Medicine

2011-Present Professor of Surgery and Director
Department of Surgery
Division of Immunology and Organ Transplantation
The University of Texas Medical School at Houston

ADMINISTRATIVE APPOINTMENTS:

2014 Chief of Abdominal Transplant
Memorial Hermann Hospital Transplant Program
Houston, Texas

2014 Director of Abdominal Transplant Program/Principal Surgeon
Memorial Hermann Hospital Transplant Program
Houston, Texas

HOSPITAL APPOINTMENTS:

1990-1991 Dothan Surgical Associates
Dothan, Alabama

1993-2000 Birmingham VAMC
WOC

1993-2011 Courtesy Staff
The Children's Hospital
Birmingham, Alabama

1993-1998 Assistant Medical Director of Alabama Organ Center
Birmingham, Alabama

1993-2011 Director, Pediatric Abdominal Transplant Program
University Hospital

1994-2011 Director, Adult Liver Transplant Program
University Hospital
Birmingham, Alabama

2011 Primary Surgeon
Liver, Kidney and Pancreas Transplantation
Memorial Hermann Hospital
Houston, Texas

2011 Program Director
Memorial Hermann Hospital Transplant Program
Houston, Texas

LICENSURE:

1987	Alabama (MD.13587)
2011	Texas (P0352)

CERTIFICATION:

1987	National Board of Medical Examiners
1993	American Board of Surgery
2003, 2014	Recertification American Board Surgery

PROFESSIONAL ORGANIZATIONS:

LOCAL:

Texas Transplantation Society

NATIONAL:

American Association for the Study of Liver Diseases
American College of Surgeons, Fellow
American Society of Transplantation
American Society of Transplant Surgeons
Association for Academic Surgery
International Liver Transplantation Society
The Society for Surgery of the Alimentary Tract, Inc.

HONORS AND AWARDS:

1994	Award of Excellence, University of Alabama Hospital
1998	Alabama Honoree for Outstanding Achievement in the Treatment of Liver Disease, American Liver Foundation
2002	Alabama Honoree for Outstanding Achievement in the Treatment of Liver Disease, American Liver Foundation
2012	Dean's Teaching Excellence Award – UTHealth, The University of Texas Medical School at Houston
2019	Houston Texas Honoree for Outstanding Achievement in the Treatment of Liver Disease, American Liver Foundation

EDITORIAL POSITIONS:

2001-2011	Ad-hoc Reviewer Liver Transplantation, W.B. Saunders Company
-----------	---

2005- Present	Ad-hoc Reviewer The American Journal of Surgery, Elsevier
2015- Present	Ad-hoc Reviewer American Journal of Transplantation, Wiley-Blackwell
2015 – Present	Ad-hoc Reviewer BMC Infectious Disease, BioMed
2013- Present	Physician Editor and Editorial Board Member Memorial Hermann Health Network Providers, Inc. (MHMD)
2016- Present	Ad-hoc Reviewer Transplant International

**SERVICE ON NATIONAL GRANT REVIEW PANELS,
STUDY SECTIONS, COMMITTEES:**

1993-2011	Medical Advisory Board of Alabama Organ Center
1993-2011	University of Alabama at Birmingham Health System Medical Staff Committee Member
1994-2011	Cost Care Clinical Efficacy Panel
1996-2011	Organ Donation Awareness Committee (UAB Hospital)
1996-2000	American Liver Foundation, Alabama Chapter, Medical Advisory Committee, Member
1996-1998	UNOS Liver and Intestine Committee, Member
1996-2001	SEOPF Liver Committee Chairman
1997-1998	UNOS Region 3 Review Board Representative/Chairman
1998-1999	UNOS Region 3 Board Member
2000-2001	UNOS Liver and Intestine Committee, Member
2000-2001	UNOS Region 3 Review Board Representative/Chairman
2000-2001	UNOS Liver and Intestine Committee, Member
2001-Present	Blue Quality Centers for Transplant Blue Cross/Blue Shield Kidney, Pancreas Liver Transplantation
2001-2011	LifeTrac Network Alliance Group Transplantation
2011-Present	Medical Advisory Committee, LifeGift Organ Donation
2011-Present	Advisory Board Committee, LifeGift Organ Donation
2012-Present	Credentials Committee, Memorial Hermann Hospital-Texas Medical Center
2012-2016	Medical Information Committee, Memorial Hermann Hospital- Texas Medical Center
2012-Present	Surgeons Council, Memorial Hermann Hospital- Texas Medical Center
2012-Present	Professional Behavior Committee, Memorial Hermann Hospital- Texas Medical Center
2012-2015	Liver Councilor, Executive Committee – Texas Transplantation Society
2012-2015	Program Committee, Texas Transplantation Society

2013-2017	Clinic Care4 Executive Oversight Committee
2013-Present	Clinic Care4 Physician Advisory Committee
2013-2017	Memorial Hermann Health Network Providers (MHMD) Clinical Programs Committee Subcommittee
2013-Present	OptumHealth Solid Organ Expert Panel
2014-Present	End Stage Renal Disease (ESRD) Network 14 of Texas Medical Review Board (MRB)
2019 – Present	National Reviewer for MELD exceptions UNOS

SERVICE TO THE COMMUNITY:

1998-2000	Patient Access to Transplantation Member
2015- Present	Board Living Bank – Houston
2015- Present	Medical Advisory, Board American Liver Foundation – Houston
2019 –Present	University of Tennessee College of Medicine Alumni Council

PREVIOUS TEACHING RESPONSIBILITIES:

1998-2003	3 rd Year Medical Student Surgery Rotation Preceptor
1998-2000	3 rd Year Medical Student Lecture, “GI Hemorrhage”
1999-2000	3 rd Year Medical Student Lecture, “Portal Hypertension”

CURRENT GRANT SUPPORT:

Principal Investigator
 BMS
 IM103-177 (Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix® (belatacept) –based Immunosuppression 6/2015- completed

Principal Investigator
 BMS
 IM103-116: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression 9/2015- completed

Principal Investigator
 Novartis Pharmaceuticals
 “A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation – Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM) 12/2015 – completed

PAST GRANT SUPPORT:

Principal Investigator

“Analysis of urinary Fibroblast Growth Factor Levels as a Marker for Acute Renal Allograft Rejection (Preclinical Model of Chronic Renal allograft Rejection)”
8/11/98 – completed

Principal Investigator

Fujisawa Healthcare, Unrestricted Grant,
Monotherapy With FK506 After Orthotopic Liver Transplantation, Fujisawa Healthcare,
unrestricted grant
1999 – completed

Principal Investigator

Novartis Pharmaceuticals

“OLN-452 Open Label Study of Neoral as Primary Immunosuppressant Therapy in Transplant Patients Who Are Unable to Maintain Satisfactory Immunosuppression on Prograf”
8/10/2000 – completed

Principal Investigator

National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Disease, National Institutes of Health.

“A Phase I/II Study to Evaluate the Safety and Pharmacokinetics of Hepatitis C Immune Globulin (Human), Civacir in Liver Transplant Recipients”
8/29/00- completed

Principal Investigator

Wyeth-Ayerst

“A Phase II, Open-Label Concentration-controlled, Randomized Study of Conventional-Dose Tacrolimus Plus Corticosteroids Compared With Reduced-Dose Tacrolimus Plus Sirolimus and Corticosteroids in Recipients of Orthotopic Liver Allografts
10/18/00 - completed

Co-Investigator

The National Institutes of Health

“A Double-Blind Randomized Trial Of Steroid Withdrawal In Sirolimus and Cyclosporine-Treated Primary Transplant Recipients, Cooperative Clinical Trials in Pediatric Transplantation (CCTPT-2)”
January 2001 – completed

Principal Investigator

Fujisawa Pharmaceuticals

“A Randomized, Comparative Trial of Prograf (Tacrolimus) in combination with Sirolimus or Mycophenolate Mofetil After Liver Transplantation”
2/12/2001 – completed

Principal Investigator

Novo-Nordisk

“A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-controlled Dose Exploratory Trial Evaluating the Safety and Efficacy of Activated Recombinant Factor VI

(rFVIIa/NovoSeven) in the Reduction of Bleeding in Subjects Undergoing Orthotopic Liver Transplantation”
4/20/2001 – completed

Principal Investigator
Novartis Pharmaceuticals
“A Multicenter, Randomized, Open-Label, Parallel-Group Study to Compare Neoral with C-2h Monitoring to Tacrolimus With Trough Monitoring in De Novo Liver Transplant Recipients”
4/20/2001 – completed

BIBLIOGRAPHY

ABSTRACTS / POSTERS:

1. Stratta RJ, Cokcora IH, LI S, Langnas AN, Ozaki CF, **Bynon** JS, Shaw BW Jr. Intrahepatic abscess after orthotopic liver transplantation. International Hepato-Biliary Pancreatic Association, September, 1992.
2. Stratta RJ, Gokcora IH, Langnas AN, Ozaki C, **Bynon** JS, Shaw BW Jr. Risk -benefit analysis of splenectomy in liver transplant recipients. International Hepato-Biliary Pancreatic Association, September, 1992.
3. **Bynon** JS, Stratta RJ, Taylor RJ, Ozaki CF, Langnas AN, Shaw BW Jr. Vascular complications after pancreas transplantation. International Hepato-Biliary Pancreatic Association, September, 1992.
4. Lowell JA, Stratta RJ, Taylor RJ, **Bynon** JS, Larsen JL. Cholecystitis and cholelithiasis in pancreas transplant recipients. Central Surgical Association, March, 1993.
5. Howe SF, Lowell JA, **Bynon** JS, Stratta RJ, Taylor RJ. Urologic complications associated with bladder-drained pancreas transplants. American Urological Association, May, 1993.
6. Lowell JA, **Bynon** JS, Stratta RJ, Taylor RJ. Improved technique for transduodenal pancreas transplant biopsy. American Urological Association, May, 1993.
7. Stratta RJ, Taylor RJ, Frisbie K, Brennan D, Lowell JA, **Bynon** JS, Cattral M. Effects of erythromycin therapy in pancreas transplant recipients. American Society of Transplant Physicians, May, 1993.
8. Heffron TG, Langnas AN, Fox IJ, Antonson DL, Mack DR, **Bynon** JS Cattral MS, Lowell JA, Pillen TJ, Sorrell MF, Vanderhoof JA, Shaw BW Jr. Pediatric living-related transplantation affords optimal donor utilization. First International Congress on Pediatric Transplantation, August, 1993.
9. **Bynon** JS, Langnas AN, Stratta RJ, Vanderhoof JA, Antonson DL, Mack DR, Fox IJ, Heffron TG, Pillen TJ, Shaw BW Jr. Hepatopulmonary syndrome and pediatric liver transplantation. First International Congress on Pediatric Transplantation, September, 1993.

10. Frenette L, Cox J, Gosdin B, Boatwright M, Doblal D, Lockhart B, Bandyopadhyay S, Steele S, Kerns D, Eckhoff D, **Bynon S**. Conjugated estrogens decrease transfusion requirements of fresh frozen plasma (FFP) and red blood cells during orthotopic liver transplantation (OLT). October 1995, *Anesthesiology* 83(3A):A282, 1995.
11. Frenette L, Cox J, Gosdin B, Boatwright M, Doblal D, Lockhart B, Bandyopadhyay S, Steele S, Kerns D, Eckhoff D, **Bynon S**. Conjugated estrogens decrease transfusion requirements of fresh frozen plasma (FFP) during orthotopic liver transplantation (OLT). Canadian Anesthetists Society, Ottawa, Canada, 1995. *Canadian Journal of Anaesthesia*. 42:A67, 1995.
12. Eckhoff DE, Zeigler ST, Hudson SL, Frenette L, **Bynon JS**. The effect of positive crossmatch in liver transplantation. The American Association for the Study of Liver Disease, November 3-7, 1995. (poster).
13. Zeigler ST, Rhynes VK, Hudson SL, **Bynon JS**, Eckhoff DE. Race is not a critical factor in orthotopic liver transplantation (OLT). The American Society for the Study of Liver Diseases, November 3-7, 1995. (poster).
14. Gaston RS, Thomas JM, Hudson SL, Deierhoi MH, Rhynes VK, Eckhoff DE, **Bynon JS**, Julian BA, Curtis JJ, Diethelm AG. Effect of HLA class I creg mismatching in cadaveric (CAD) renal transplantation. American Society of Transplant Physicians 15th Annual Meeting, May 26-30, 1996.
15. Thomas JM, Gaston RS, Hudson SL, Deierhoi MH, Rhynes VK, Eckhoff DE, **Bynon JS**, Julian BA, Curtis JJ, Benfield MR, Diethelm AG. Effect of HLA class I creg mismatching in cadaveric (CAD) renal transplantation. XVI International Congress of the Transplantation Society, August 25-30, 1996
16. Eckhoff DE, Ingram CO, Frenette L, Cox J, McGuire BM, **Bynon S**. Tacrolimus (FK506) and mycophenolate[mofetil (MMF) combination therapy versus tacrolimus in adult liver transplantation. 16th Annual Meeting of the American Society of Transplant Physicians, May 10-14, 1997.
17. Frenette L, Cox J, Eckhoff D, **Bynon JS**, Arnall M. Prospective randomized study shows a decrease in blood product utilization when conjugated estrogen (Premarin) is compared to placebo during orthotopic liver transplantation (OLT). 54th Annual Meeting of the Canadian Anaesthetists Society in Vancouver, British Columbia, Canada, June 1997.
18. Eckhoff DE, McGuire BM, Frenette L, Cox JW, Hudson SL, **Bynon JS**. Race is not a critical factor in orthotopic liver transplantation (OLT). Samuel Kountz Symposium, July 9, 1997.
19. McGuire BM, Eckhoff DE, Hudson SL, Cox J, Frenette L, **Bynon JS**. Should we obtain human leukocyte antigens (HLA) in donors and recipients for liver transplantation? International Liver Transplantation Society, Seattle, WA. October 1997. (poster)
20. Frenette L, Cox J, Arnall LM, Eckhoff D, **Bynon S**. Conjugated Estrogen decreases red blood cell and fresh frozen plasma transfusion in liver transplantation. 4th Congress International Liver Transplantation Society, October 15-17, 1997.

21. Eckhoff DE, Frenette L, Cox J, McGuire BM, Ingram CO, **Bynon JS**. Tacrolimus (FK506) and mycophenolate mofetil (MMF) combination therapy versus tacrolimus in adult liver transplantation. 4th Congress International Liver Transplantation Society, October 15-17, 1997.
22. McGuire BM, Eckhoff DE, Hudson SL, Cox J, Frenette L, **Bynon JS**. Should we obtain human leukocyte antigens (HLA) in donors and recipients for liver transplantation? 4th Congress International Liver Transplantation Society, October 15-17, 1997. (poster)
23. Eckhoff DE, McGuire BM, Frenette L, Cox JW, Hudson SL, **Bynon JS**. Race is not a critical factor in orthotopic liver transplantation (OLT). 4th congress International Liver Transplantation Society, Oct 15-17, 1997 (poster).
24. Frenette L, Cox J, Eckhoff DE, **Bynon JS**, Arnall M. Prospective randomized study shows a decrease in blood product utilization when conjugated estrogen (Premarin) is compared to placebo during orthotopic liver transplantation (OLT). The International Liver Transplantation Society Meeting in Seattle, Washington, October 1997.
25. Abrams GA, Fallon MB, Nanda NC, Eckhoff DE, **Bynon JS**. Utility of pulmonary function tests, arterial blood gas and echocardiography in the pre-operative evaluation for liver transplantation. 48th Annual Meeting of the American Association for the Study of Liver Diseases in Chicago, Illinois, November 7-11, 1997.
26. Cretton-Scott E, Placidi L, Eckhoff D, **Bynon S**, Sommadossis JP. Long-term primary cultures of hepatocytes in serum free medium. 48th Annual Meeting of the American Association for the Study of Liver Diseases in Chicago, Illinois, November 7-11, 1997.
27. Eckhoff DE, McGuire BM, Young CJ, Sellers MT, Frenette L, Hudson SL, Contreras J, **Bynon JS**. Race: A critical factor in organ donation, patient selection, and orthotopic liver transplantation? 17th Annual Scientific Meeting of ASTP, Chicago, May 9-13, 1998. (poster)
28. Frenette L, Cox J, McArdle P, Eckhoff D, **Bynon S**. Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. *Anes Analg* 1998;86:1183-6.
29. Eckhoff DE, Sellers MT, Contreras JL, Benfield MR, Kohaut EC, Hudson SL, Diethelm AG, **Bynon JS**. The evolving challenges of pediatric renal transplantation. Third International Congress on Pediatric Transplantation, Boston, July 8-10, 1998. (poster)
30. Matern D, Starzl TE, Arnaout W, Barnard J, **Bynon JS**, Shawan A, Emond J, Haagsma EB, Hug G, Lachaux A, Smit GPA, Chen YT. Liver transplantation for glycogen storage disease types I, III, and IV. *Eur J Pediatr* (1999) 158 (Suppl 2): S43-S48.
31. Eckhoff D, Frenette L, Cox J, Hudson S, **Bynon J**. Liver transplantation in the era of managed care. Southeastern Surgical Congress, Tampa, Florida, February 15-17, 1999.
32. Eckhoff D, Contreras J, Sellers M, McGuire B, **Bynon J**. Complications of hepaticojejunostomy in liver transplantation. 1999 Americas Hepato-Pancreato-Biliary

Congress, February 18-21, 1999.

33. Eckhoff D, Baron T, Blackard W, Morgan D, Crowe R, Sellers M, McGuire B, Contreras J, **Bynon J**. The role of ERCP in asymptomatic orthotopic liver transplant patients with abnormal liver enzymes. 1999 Americas Hepato-Pancreato-Biliary Congress, February 18-21, 1999.
34. Frenette L, Smith B, Cross C, Contreras J, Sellers M, **Bynon S**, Eckhoff D. Ionized hypomagnesemia in orthotopic liver transplantation (olt). Do we need to treat it? Canadian Anesthesiologists Society Meeting, June 21, 1999.
35. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Hudson S, Ingram C, **Bynon S**. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant patients. The 18th Annual Meeting of the American Society of Transplantation (AST) Chicago, Illinois, May 15-19, 1999.
36. Sellers MT, Hudson SL, Young CJ, **Bynon JS**, Eckhoff DE, Gallichio MH, Deierhoi MH, Diethelm AG, Thompson JA. Improved outcomes in cadaveric renal allografts with pulsatile preservation. The 25th Annual Scientific Meeting of the American Society of Transplant Surgeons (ASTS) Chicago, Illinois, May 19-21, 1999.
37. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Hudson S, Ingram C, **Bynon S**. The safety and efficacy of two-dose daclizumab (zenapax) induction therapy in liver transplant patients. Minneapolis Transplant Congress, Minneapolis, Minnesota, October 20-23, 1999.
38. McGuire BM, Eckhoff De, Hudson S, Wilson P, Maharrey B, Davis P, **Bynon JS**, Sellers MT. Safety of steroid withdrawal in 291 liver transplant patients. Minneapolis Transplant Congress, Minneapolis, Minnesota, October 20-23, 1999.
39. Sellers M, **Bynon J**, Eckhoff D, Chan C, Heslin M. Laparoscopic radiofrequency ablation for hepatocellular carcinoma in advanced cirrhosis. First Joint Annual Meeting of ASTS and AST (Transplant 2000), Chicago, Illinois, May 13-17, 2000.
40. Abouljoud M, Kumar MSA, Brayman K, Emre S, **Bynon JS**. Conversion to neoral® provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf®. American Society of Transplantation (AST), Chicago, IL, May 13-17, 2000. (poster)
41. Sellers MT, McGuire BM, Eckhoff DE, Hudson SL, **Bynon JS**. Feasibility of steroid withdrawal in liver transplantation – an experience with 288 patients. First Joint Annual Meeting of ASTS and AST (Transplant 2000), Chicago, Illinois, May 13-17, 2000.
42. Sellers M, **Bynon J**, Eckhoff D, Chan C, Heslin M. Laparoscopic radiofrequency ablation for hepatocellular carcinoma in advanced cirrhosis. International Hepato-Pancreato-Biliary Association, Queensland Australia, May 28-June 1, 2000.
43. Sellers MT, McGuire BM, Eckhoff DE, **Bynon JS**, Hudson SL, Deierhoi MH, Diethelm AG. Feasibility of steroid withdrawal after liver transplantation – an experience with 288 patients. XVIII International Congress of the Transplantation Society, Rome, Italy, August 27 – September 1, 2000.

44. Abouljoud M, Kumar MSA, Brayman K, Emre S, **Bynon JS**. Conversion to neoral® provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf, ISOT meeting, Rome, Italy, August, 2000.
45. Sellers MT, McGuire BM, Haustein SV, **Bynon JS**, Hudson SL, Eckhoff DE. Long-term follow-up of daclizumab induction in liver transplant recipients. American Transplant Congress (ASTS and AST), Washington, D.C., April 26-May 1, 2002.
46. McGuire BM, McGwin G, Owsley, Eckhoff DE, **Bynon JS**, Bush BA, Fallon MB. Patients evaluated for liver transplant with hepatic encephalopathy have increased risks of automobile crashes. American Transplant Congress, Washington, D.C., May 30 – June 4, 2003.
47. McGuire BM, **Bynon JS**, Julian BA, King SJ, Cook WJ, Comeaux B, Eckhoff DE. High prevalence of glomerulonephritis in end-stage hepatitis C cirrhosis. American Association for the Study of Liver Diseases, San Francisco, CA. November 13, 2005. Hepatology 2005;42(4 Suppl 1):481A.
48. Morgan, DE, Lockhart, ME, Canon, CL, **Bynon J**. Polycystic Liver Disease: Multimodality Imaging for Complications and Transplant Evaluation. 91st Scientific Assembly and Annual Meeting of the Radiological Society of North American, Chicago, IL., November 27 – December 2, 2005. (poster)
49. Novak L, Novak J, McGuire BM, Brown R, Hall S, Newsome B, Tomana M, Mestecky J, Eckhoff DE, **Bynon JS**, Julian B. Primary IgA nephropathy (IgAN) and IgAN in patients with hepatitis C virus (HCV)-induced cirrhosis: cellular proliferation of cultured mesangial cells after stimulation with circulating immune complexes (CIC) and morphometric analysis of renal biopsies. 11th International Symposium of IgA Nephropathy, October 5-7, 2006, Tokyo, Japan. (poster)
50. McGuire BM, Julian BA, Novak J, **Bynon JS**, Cook WJ, Eddleman S, Eckhoff DE. High prevalence of glomerulonephritis in patients with end-stage HCV-induced cirrhosis. The Liver Meeting, October 28-31, 2006. Hepatology 2007;44:533A.
51. McGuire BM, Julian BA, Novak J, **Bynon JS**, Cook WJ, Vincent JM, Eckhoff DE. Patients with HCV-induced cirrhosis with immune-complex glomerulonephritis have progressive proteinuria after liver transplantation. The Liver Meeting, Boston, MA., October 28-31, 2006. Hepatology 2007;46:539A.
52. McGuire BM, Julian BA, Novak J, **Bynon JS**, Cook WJ, Vincent JM, Eckhoff DE. Patients with HCV-induced cirrhosis with immune-complex glomerulonephritis have progressive proteinuria after liver transplantation. 58th Annual Meeting of the AASLD, November 2-6, 2007 in Boston, MA.
53. McGuire BM, Julian BA, Novak J, **Bynon JS**, Cook WJ, Eddleman S, Eckhoff DE. High prevalence of glomerulonephritis in patients with end-stage HCV induced cirrhosis compared to non-viral induced cirrhosis. 58th Annual Meeting of the AASLD, November 2-6, 2007 in Boston, MA.

54. Pivalizza EG, Marasigan B, Reyes-Guzman S, Melnikov V, Quintana O, Riha K, Gumbert SD, **Bynon JS**. Effect of the surgeon on bleeding and transfusion for liver transplantation. American Society of Anesthesiologists (ASA) Annual Meeting - Anesthesiology 2012, Washington, DC. October 13 – 17, 2012. (abstract)
55. Samuel JP, Bell CS, **Bynon JS**, Samuels, JA, Swinford RD. Predictors of early and late graft loss in recipients with kidneys from the same donor: analysis of the UNOS database. American Society of Nephrology (ASN) Kidney Week 2012, San Diego, CA. October 30-November 4, 2012. JASN 23:580A, 2012. (abstract)
56. Ling M, **Bynon JS**. Application of herbal complement inhibitors to solid organ transplant with highly sensitized patients and other inflammatory disorders. Inaugural TexasAIR Roundtable, Austin, TX. September 25-26, 2013. (poster)
57. Assylbekova B, Mauzo S, Bynon JS, Wahed A, Nedelcu E, Bhattacharjee MB. Giant cavernous hepatic hemangioma and multicystic biliary hamartoma: an unusual association. College of American Pathologists 2013 (CAP 2013) Meeting, Kissimmee, FL, October 13-16, 2013 (poster).
58. Dierksen JE, Jacobi E, Bhattacharjee M, **Bynon JS**. Recurrence of a biliary mucinous cystadenoma in a woman with a ovarian dermoid cyst. Texas Society of Pathologists 93rd Annual Meeting, Houston, TX, January 17-19, 2014 (abstract)
59. Chen G, Bell P, Loughhead P, Ibeche J, Bynon JS, Hall DR, De Golovine A, Edwards A, Dar WA. Exploration of the Stanford Integrated Psychosocial Assessment for Transplantation with Psychosocial and Medical Outcomes in Kidney/Kidney-Pancreas Transplantation. American Transplant Congress 2019, Boston MA. June 1-5, 2019 (poster).
60. Estrada MM, Hall DR, Dar WA, Bynon JS. Page Kidney Phenomenon in a Trauma Patient: A Case Report and Recommendations for Management. American Transplant Congress 2019, Boston MA. June 1-5, 2019. (poster).
61. Swinford RD, De Golovine A, Bell C, Pai A, Edwards, AR, Conner S, Bynon JS. Donor-Derived Cell-Free DNA (dd-cfDNA) Course after Rejection in Pediatric Kidney Transplant Recipients. American Transplant Congress 2019. Boston MA. June 1-5, 2019. (poster).

PUBLICATIONS:

1. Ozaki CF, Stratta RJ, Taylor RJ, Langnas AN, **Bynon JS**, Shaw BW Jr. Surgical complications in solitary pancreas and combined pancreas-kidney transplantations. Am J of Surg 164(5):546-51, 1992.
2. Langnas AN, Stratta RJ, Wood RP, Ozaki CF, **Bynon JS**, Shaw BW Jr. The role of intrahepatic cholangiojejunostomy in liver transplant recipients after extensive destruction of the extrahepatic biliary system. Surgery 112(4):712-7; discussion 717-8, 1992.

3. Stratta RJ, Taylor RJ, Ozaki CF, **Bynon** JS, Langnas AN, Shaw BW Jr. Combined pancreas-kidney transplantation versus kidney transplantation alone: analysis of benefit and risk. *Transplant Proc* 25(1 Pt 2):1298-301, 1993.
4. Langnas AN, Inagaki M, **Bynon** JS, Ozaki CF, Stratta RJ, Shaw BW Jr. Hepatic retransplantation in children. *Transplant Proc* 25(2):1921-2, 1993.
5. Stratta RJ, Taylor RJ, Wahl TO, Duckworth WC, Gallagher TF, Knight TF, Fischer JL, Neumann TV, Miller SA, Langnas AN, Ozaki CF, **Bynon** JS, Larsen JL, Weide LG, Cassling RS, Taylor RJ, Shaw BW Jr. Recipient selection and evaluation for vascularized pancreas transplantation. *Transplantation* 55(5):1090-6, 1993.
6. Stratta RJ, Taylor RJ, Ozaki CF, **Bynon** JS, Miller SA, Knight TF, Fischer JL, Neumann TV, Wahl TO, Duckworth WC. et al. A comparative analysis of results and morbidity in type I diabetics undergoing preemptive versus postdialysis combined pancreas-kidney transplantation. *Transplantation* 55(5): 1097-103, 1993.
7. Lowell JA, **Bynon** JS, Stratta RJ, Taylor RJ. Superior mesenteric arteriovenous fistula in vascularized whole organ pancreatic allograft. *Surgery, Gynecology & Obstetrics*. 177(3):254-8, 1993.
8. Lowell JA, Stratta RJ, Taylor RJ, **Bynon** JS, Larsen JL, Nelson NL. Cholelithiasis in pancreas and kidney transplant recipients with diabetes. *Surgery* 114(4):858-63; discussion 863-4, 1993.
9. **Bynon** JS, Stratta RJ, Taylor RJ, Lowell JA, Cattral M. Vascular reconstruction in 105 consecutive pancreas transplants. *Transplant Proc* 25(6):3288-9,1993.
10. Stratta RJ, Taylor RJ, Lowell JA, **Bynon** JS. Selective use of Sandostatin in vascularized pancreas transplantation. *Amer J Surg* 166:598-605, 1993.
11. Stratta RJ, Taylor RJ, Ozaki CF, **Bynon** JS, Miller SA, Baker TL, Lykke C, Krobot ME, Langnas AN, Shaw BW Jr. The analysis of benefit and risk of combined pancreatic and renal transplantation versus renal transplantation alone. *Surg Gynecol Obstet* 177:163-171, 1993.
12. Stratta RJ, Taylor RJ, Lowell JA, **Bynon** JS, Cattral MS, Frisbie K, Brennan DC. A randomized trial of Sandostatin prophylaxis for preservation injury and pancreas transplantation. *Transplant Proc* 25(6):3190-3192, 1993.
13. Stratta RJ, Taylor RJ, Ozaki CF, **Bynon** JS, Langnas AN, Shaw BW Jr. Combined pancreas-kidney versus kidney transplantation alone. Analysis of benefit and risk. *Transplant Proc* 25(1):1298-1301, 1993.
14. **Bynon** JS, Hudson SL, Kohaut EC, Benfield MR, Waldo FB, Diethelm AG. Pediatric renal transplantation at the University of Alabama at Birmingham, 1968 to 1993. *Clin Transp* 1993:259-65.
15. Heffron TG, Antonson DI, Langnas AN, Fox IJ, Mack DR, **Bynon** JS, Cattral MS, Lowell JA, Pillen TJ, Sorrell MF, et al. Pediatric living related transplantation affords optimal donor utilization. *Transplant Proc* 26(1):144, 1994.

16. Ozaki CF, Langnas AN, **Bynon** JS, Pillen TJ, Kangas J, Vogel JE, Shaw BW Jr. A percutaneous method for venovenous bypass in liver transplantation. *Transplantation* 57(3):472-3, 1994.
17. Stratta RJ, Taylor RJ,, **Bynon** JS, Lowell JA, Cattral MS, Frisbie K, Miller S, Radio SJ, Brennan DC. Viral prophylaxis in combined pancreas-kidney transplant recipients. *Transplantation* 57(4):506-12, 1994
18. Lowell JA, **Bynon** JS, Nelson N, Hapke MR, Morton JJ, Brennan DC, Radio SJ, Stratta RJ, Taylor RJ. Improved technique for transduodenal pancreas transplant biopsy *Transplantation* 57(5):752-3, 1994.
19. Stratta RJ. Taylor RJ, Lowell JA. **Bynon** JS, Cattral MS, Brennan DC, Weide LG, Duckworth WC. Preemptive combined pancreas-kidney transplantation: is earlier better? *Transplant Proc* 26(2):422-4, 1994.
20. Stratta RJ, Taylor RJ, **Bynon** JS, Lowell JA, Frisbie K, Brennan DC, Radio SJ, Cattral MS. Patterns of rejection after combined pancreas-kidney transplantation. *Transplant Proc* 26(2):524-5, 1994.
21. Stratta RJ, Taylor RJ, Lowell JA, **Bynon** JS, Cattral MS, Frisbie K, Miller S, Brennan DC. OKT3 induction in 100 consecutive pancreas transplants. *Transplant Proc* 26(2):546-7, 1994.
22. Cattral MS, Langnas AN, Wisecarver JL, Harper JC, Rubocki RJ, **Bynon** JS, Fox IJ, Heffron TG, Shaw BW Jr. Survival of graft-versus-host disease in a liver transplant recipient. *Transplantation* 57(8):1271-4, 1994.
23. Taylor RJ, **Bynon** JS, Stratta RJ. Kidney/pancreas transplantation: a review of the current status. *Urol Clin North Am* 21(2):343-54. Review. 1994.
24. Lowell JA, Taylor RJ, Cattral M, **Bynon** JS, Brennan DC, Stratta RJ. En bloc transplantation of a horseshoe kidney from a high risk multi-organ donor: case report and review of the literature. *Journal of Urology* 152(2 Pt 1):468-70, 1994.
25. Stratta RJ, Taylor RJ, **Bynon** JS, Lowell JA, Sindhi R, Wahl TO, Knight TF, Weide LG, Duckworth WC. Surgical treatment of diabetes mellitus with pancreas transplantation *Annals of Surgery* 220(6):809-17, 1994.
26. Stratta RJ, Taylor RJ, Lowell JA, **Bynon** JS, Brennan D, Frisbie K, Cattral M. Patterns of rejection after combined pancreas-kidney transplantation. *Transplant Proc* 25:524-525, 1994.
27. Diethelm AG, Deierhoi MH, Hudson SL, Laskow DA, Julian BA, Gaston RS, **Bynon** JS, Curtis JJ. Progress in renal transplantation. A single center study of 3359 patients over 25 years. *Annals of Surgery* 221(5):446-57; discussion 457-8, 1995.
28. Sindhi R, Stratta RJ, Taylor RJ, Lowell JA, Sudan D, Castaldo P, **Bynon** JS, Pillen TJ. Increased risk of pulmonary edema in diabetic patients undergoing preemptive pancreas transplantation with OKT3 induction. *Transplant Proc* 27(6):3016-7, 1995.

29. Lowell JA, Stratta RJ, Taylor RJ, **Bynon JS**. Mesenteric arteriovenous fistula after vascularized pancreas transplantation resulting in graft dysfunction. *Clin Transp* 10(3):278-81, 1996.
30. Vickers SM, Phillips JO, Kerby JD, **Bynon JS Jr**, Thompson JA, Curiel DT. In vivo gene transfer to the human biliary tract. *Gene Therapy* 3(9):825-8, 1996
31. Frenette L, Cox J, Sinder D, Ronderos J, Steele S, Eckhoff D, **Bynon S**. Five years of experience with percutaneous cannula for establishing venous bypass access in orthotopic liver transplantation. *Transplant Proc* 28(5):2974-2977, 1996.
32. Eckhoff DE, McGuire BM, Young CC, Frenette L, Hudson SL, Contreras J, **Bynon JS**. Race is not a critical factor in orthotopic liver transplantation. *Transplant Proc*. 29(8):3729-30, 1997.
33. Eckhoff DE, Ingram CO, Frenette L, Cox J, McGuire BM, **Bynon JS**. Tacrolimus (FK506) and mycophenolate mofetil (MMF) combination therapy versus tacrolimus in adult liver transplantation. *Transplantation* 63(7):A33, 1997.
34. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, **Bynon JS**. Tacrolimus (FK506) and mycophenolate mofetil (MMF) combination therapy versus tacrolimus in adult liver transplantation. *Transplantation* 65(2):180-187, 1998.
35. Frenette L, Cox J, Eckhoff D, **Bynon JS**, Arnall M. Effectiveness of conjugated estrogens in orthotopic liver transplantation. *Southern Medical Journal* Vol. 91(4):365-368, 1998.
36. Frenette L, Cox J, McArdle P, Eckhoff D, **Bynon S**. Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. *Anesth Analg* 86:1183-6, 1998.
37. Eckhoff D, McGuire B, Young C, Sellers M, Frenette L, Hudson S, Contreras J, **Bynon S**. Race: A critical factor in organ donation, patient referral and selection, and orthotopic liver transplantation? *Liver Transplantation and Surgery* 4(6):499-505, 1998.
38. Eckhoff DE, McGuire B, Young C, Frenette L, Hudson SH, Contreras JL, **Bynon S**. Race is not a critical factor in orthotopic liver transplantation. *Transplant Proc* 29: 3729, 1998.
39. Eckhoff DE, McGuire B, Young CJ, Sellers MT, Frenette L, Hudson SL, Contreras J, **Bynon JS**. Race: A critical factor in organ donation, patient selection, and orthotopic liver transplantation? *Transplantation* 65(7):A273, 1998
40. Sood G, Fallon MB, Niwas S, Tutton T, vanLeeuwen DJ, Bloomer JR, McGuire BM, Sellers MT, Eckhoff DE, **Bynon JS**, Abrams GA. Utility of a dyspnea-fatigue index for screening liver transplant candidates for hepatopulmonary syndrome. *Hepatology* 28(4):742A, 1998.
41. Benfield MR, Symons JM, **Bynon S**, Eckhoff D, Herrin J, Harmon WE, Kohaut EC.

Mycophenolate mofetil in pediatric renal transplantation. *Pediatric Transplantation* a. 3: 33-37, 1999.

42. Frenette L, Smith B, Cross C, Contreras J, Sellers M, **Bynon** S, Eckhoff D. Ionized hypomagnesemia in orthotopic liver transplantation (olt). Do we need to treat it? *Canadian Journal of Anesthesia* 46(5):A44, 1999.
43. Placidi L, Scott EC, Eckhoff D, **Bynon** S, Sommadossi JP. Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes. *Drug Metab Dispos* 27(5):623-6, 1999.
44. Abrams GA, Rose K, Fallon MB, McGuire BM, Bloomer JR, van Leeuwen DJ, Tutton T, Sellers MT, Eckhoff DE, **Bynon** JS. Hepatopulmonary Syndrome and Venous Emboli Causing Intracerebral Hemorrhages after Liver Transplantation: A Case Report. *Transplantation* 68(11):1809-11, 1999
45. Matern D, Starzl TE, Arnaout W, Barnard J, **Bynon** JS, Shawan A, Edmond J, Haagsma EB, Hug G, Lachaux A, Smit P, Chen YT. Liver transplantation for glycogen storage disease types I, III, and IV. *Eur J Pediatr* 158 Suppl 2:S43-8, Review, 1999.
46. Arguedas MR, McGuire BM, Fallon MB, Abrams, GA, vanLeeuwen DJ, **Bynon** JS, Eckhoff DE, Sellers MT, Bloomer JR. The use of screening and preventive therapies for esophageal varices in patients referred for evaluation of orthotopic liver transplantation. *Hepatology* 30(4):A220, 1999.
47. Abrams GA, Fallon MB, Nail C, McGuire BM, vanLeeuwen DJ, Eckhoff DE, **Bynon** JS, Bloomer JR. Pulse Oximetry: Utility in detecting arterial hypoxemia in subjects with cirrhosis. *Hepatology* 30(4):A1099, 1999.
48. Eckhoff DE, McGuire BM, Sellers M, Contreras J, Frenette L, Hudson S, Ingram C, **Bynon** S. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant patients. *Transplantation* 67(7):A101, 1999.
49. Eckhoff DE, Baron TH, Blackard WG, Morgan DE, Crowe R, Sellers M, McGuire B, Contreras JL, **Bynon** JS. Role of ERCP in asymptomatic orthotopic liver transplant patients with abnormal liver enzymes. *American Journal of Gastroenterology* 95:1 141-144, 2000.
50. Eckhoff DE, McGuire BM, Young C, Sellers MT, Contreras JL. Frenette LR, Hudson SL, **Bynon** JS. Liver transplantation in the era of cost constraints. *Southern Medical Journal* 93(4)392-396, 2000.
51. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, **Bynon** JS. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. *Transplantation* (69) 1867-1872, No. 9, 2000 May 15;69(9):1867-72.
52. Baron TH, Yates M III, Morgan DE, Eckhoff DE, **Bynon** JS. Biliary cast syndrome: Successful endoscopic treatment. *Gastrointestinal Endoscopy* 52(1):78-9. 2000.
53. Sellers MT, Gallichio MH, Hudson SL, Young CJ, **Bynon** JS. Eckhoff DE, Deierhoi MH,

- Deithelm AG, Thompson JA. Improved outcomes in cadaveric renal allografts with pulsatile preservation. *Clinical Transplantation* 14(6):543-549, 2000.
54. Sellers MT, McGuire BM, Eckhoff DE, Hudson SL, **Bynon** JS. Feasibility of steroid withdrawal in liver transplantation. *Transplantation* 69(8):A1064, 2000.
55. Eckhoff DE, Frenette L, Sellers MT, McGuire BM, Contreras JL, **Bynon** JS, McGiffin DC. Combined cardiac surgery and liver transplantation. *Liver Transplantation* 7(1):60-61, 2001.
56. Abouljoud M, Kumar MS, Brayman K, Emre S, **Bynon** JS. Conversion to neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. *Transplant Proc* 33(1-2):1027-8, 2001. Feb-Mar;33(1-2):1027-8
57. Medina-Franco H, Sellers MT, Eckhoff DE, **Bynon** JS, Urist MM, Heslin MJ. Multimodality treatment for patients with hepatocellular carcinoma: analysis of prognostic factors in a single western institutional series. *J GI Surg Vol* 5(6):638-645, 2001. Nov-Dec;5(6):638-45.
58. Sellers MT, Haustein SV, McGuire BM, Jones C, **Bynon** JS, Diethelm AG, Eckhoff DE. Use of preserved vascular homograft in liver transplantation: hepatic artery aneurysms and other complications. *American Journal of Transplantation* 2(5):471-475, 2002.
59. Abouljoud MS, Kumar MS, Brayman KL, Emre S, **Bynon** JS. Neoral rescue therapy in transplant patients with intolerance to tacrolimus. *Clin Transplant* 16(3):168-72, 2002 June;16(3):168-72
60. Haustein SV, McGuire BM, Eckhoff DE, Hudson SI, **Bynon** JS, Sellers MT. Impact of noncompliance and donor/recipient race matching on chronic liver rejection. *Transplant Proc* 34(5) 1497-1498, 2002.
61. Zoghni, Gilbert J, Patel, Amar D., Ershadi, Reza E., Heo, Jaekyeong, **Bynon**, JS, Iskandrian, Ami E.: Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation. *The Am J Cardiol* 92(9):1066-1071, 2003.
62. Arch-Ferrer JI, Smith JK, **Bynon** S, Eckhoff DE, Sellers MT, bland KI, Heslin MJ. Radio-frequency ablation in cirrhotic patients with hepatocellular carcinoma. *Am Surg* 69(12): 1067-71, 2003
63. Kolettis PN, Bugg CE, Lockhart ME, **Bynon** SJ, Burns JR. Outcomes for live donor renal transplantation using kidneys with meical fibroplasia. *Urology*. 2004 Apr;63(4):656-9 PMID: 15072873.
64. Sellers MT, McGuire BM, Haustein SV, **Bynon** JS, Hunt SL, Eckhoff DE. Two-dose daclizumab induction therapy in 209 liver transplants – a single center analysis. *Transplantation* 78(8)1212-7, 2004.
65. McGuire BM, Julian BA, **Bynon** JS, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. *Annals of Internal Medicine* 144(10):735-741,2006.

66. Morgan DE, Lockhart ME, Canon CL, Holcombe MP, **Bynon** JS. Polycystic liver disease: multimodality imaging for complications and transplant evaluation. *Radiographics* 26(6):1655-68, 2006.
67. Lang JD, Teng X, Chumley P, Crawford JH, Isbell S, Chacko BK, Liu Y, Jhala N, Crowe DR, Smith AB, Cross RC, Frenette L, Kelley EE, Wilhite DW, Hall CR, Page GP, Gallon M, **Bynon** JS, Eckhoff DE, Patel RP. Inhaled nitric oxide accelerates restoration of liver function in adults following orthotopic liver transplantation. *Journal of Clinical Invest* 117(9):2583-91, 2007.
68. Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, Liu Y, Jhala N, Crowe DR, Smith AB, Cross RC, Frenette L, Kelley EE, Wilhite DW, Hall CR, Page GP, Fallon MB, **Bynon** JS, Eckhoff DE, Patel RP. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. *J Clin Invest*. 2007 Sep;117(9):2583-91 PMID: 17717604
69. Howard JH, Tzeng CW, Smith JK, Eckhoff DE, **Bynon**, JS Want T, Arnoletti JP, Heslin MJ. Radiofrequency ablation for unresectable tumors of the liver. *Am Surg* 74(7):594-600; discussion 600-1, 2008.
70. Hage FG, Bravo PE, Zoghbi GJ, **Bynon** JS, Aqel RA. Hypertrophic obstructive cardiomyopathy in liver transplant patients. *Cardiol J* 15(1):74-9, 2008. PMID: 18646476
71. Howard JH, Tzeng CW, Smith JK, Eckhoff DE, **Bynon** JS, Wang T, Arnoletti JP, Heslin MJ. Radiofrequency ablation for unresectable tumors of the liver. *AM Surg*. 2008 Jul;74(7):594-600; discussion 600-1. PMID: 1864676.
72. Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, Lockhart SR, Chiller T, **Bynon** JS Jr, Bower WA. Transmission of *Cryptococcus neoformans* by Organ Transplantation. *Clin Infect Dis* 15;52(4):e94-8, 2011. Epub 2011 Jan 10.
73. Boeka AG, Solomon AC, Lokken K, McGuire BM, **Bynon** JS. A biopsychosocial approach to liver transplant evaluation in two patients with Wilson's disease. *Psychol Health Med* 16(3):268-75, 2011.
74. Crowe A, Knight CS, Jhala D, **Bynon** SJ, Jhala NC. Diagnosis of metastatic fibrolamellar hepatocellular carcinoma by endoscopic ultrasound-guided fine needle aspiration. *Cytojournal*. 2011 Jan 31;8:2. doi: 10.4103/1742-6413.76495. PMID: 21369523.
75. Braddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, Lockhart SR, Chiller T, **Bynon** JS Jr, Bower WA. Transmission of *Cryptococcus neoformans* by Organ Transplantation. *Clin Infect Dis*. 2011 Feb 15;52(4):e94-8. doi: 10.1093/cid/ciq216. Epub 2011 Jan 10. PMID: 21220771.
76. Machicao VI, Batra S, Mehta S, Dasher KJ, Pan, JJ, Dar WA, Hobeika MJ, **Bynon** JS, Fallon MB. Regional differences in the outcome of liver transplantation for hepatocellular carcinoma beyond Milan criteria. *Transplant Outcomes and Immunosuppression*. *Hepatology*, 58(S1): 1011A–1042A. doi: 10.1002/hep.26876, 2013. (abstract)

77. Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, Jones R, Migliaccio M, Prestele H, Orsenigo R. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. *Am J Transplant*. 2014 Mar;14(3):635-46. doi: 10.1111/ajt.12620. Epub 2014 Jan 23. PMID: 24456049.
78. Lang JD Jr, Smith AB, Brandon A, Bradley KM, Liu Y, Li W, Crowe DR, Jhala NC, Cross RC, Frenette L, Martay K, Vater YL, Vitin AA, Dembo GA, Dubay DA, **Bynon JS**, Szychowski JM, Reyes JD, Halldorson JB, Rayhill SC, Dick AA, Bakthavatsalam R, Brandenberger J, Broeckel-Elrod JA, Sissons-Ross L, Jordan T, Chen LY, Siriussawakul A, Eckhoff DE, Patel RP. A Randomized Clinical Trial Testing the Anti-Inflammatory Effects of Preemptive Inhaled Nitric Oxide in Human Liver Transplantation. *PLOS One* 9(2):e86053. eCollection 2014. PMID: 24533048.
79. Batra S, Machicao VI, **Bynon JS**, Mehta S, Tanikella R, Krowka MJ, Zacks S, Trotter J, Roberts KE, Brown RS, Kawut SM, Fallon MB; Pulmonary Vascular Complications of Liver Disease Group. The impact of left ventricular hypertrophy on survival in candidates for liver transplantation. *Liver Transpl* Jun 20(6):705-12. doi: 10.1002/lt.23875. PMID: 24659368, 2014.
80. Imseis EM, **Bynon JS**, Thornhill C. Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era. *World J Hepatol*. 2017 Mar 28;9(9):487-490. doi: 10.4254/wjh.v9.i9.487. PMID: 28396719.
81. Hobeika MJ, Dar WA, Hall DR, **Bynon JS**. Retrograde Flushing of Living Donor Renal Allografts via the Renal Vein: A Simple, Effective Technique. *Transplantation*. 2017 Sep; 101(9):2111-2114. doi: 10.1097/TP.0000000000001525. PMID: 28518062.
82. Kirtane T, Goyal D, Rahimi E, Ertan A, Bynon JS, Thosani N. Refractory bile leak with biliocutaneous fistula treated by endobiliary coil placement. *Endoscopy*. 2017 Dec;49(12):1280-1281.
83. Hebert SA, Swinford RD, Hall DR, AU JK, Bynon JS. Special Considerations in Pediatric Kidney Transplantation. *Adv Chronic Kidney Dis*. 2017 Nov;24(6):398-404.
84. Dar WA, Sullivan E, Bynon JS, Eltzhig H, Ju C. Ischemia reperfusion injury in liver transplantation: cellular and molecular mechanisms. *Liver Int*. 2019 May;39(5):788-801.
85. Nowbakht C, Edwards AR, Rodriguez-Buritica DF, Luce AM, Doshi PB, De Golovine A, Bynon JS, Nigo M. *Open Forum Infect Dis*. 2019 Mar 4;6(3):ofz033.doi:10.10093/ofid/ofz033.eCollection 2019 Mar.
86. Polireddy K, Singh K, Pruski M, Jones NC, Manisundaram NV, Ponnella P, Quелlette M, Van Buren G, Younes M, Bynon JS, Dar WA, Bailey JM. *Caner Lett*.2019 Jul 1;453:122-130. Doi:10.1016/j.canlet.2019.03.047. E[ub 2019 Apr 1.
87. Chen g, Bell CS, Loughhead P, Ibeche B, Bynon JS, Hall DR, De Golovine A, Edwards A, Dar WA. Exploration of the Stanford Integrated Psychosocial Assessment for Transplantation with Psychosocial and Medical Outcomes in Kidney and Kidney-Pancreas Recipients. *Prog Transplant*. 2019 Sept;29(3):230-238. Doi:10.1177/1526924819854480. Epub 2019 May 20.

88. Cen P, Wray CJ, Zhang S, Thosani NC, Dinh BC, Gonzalez A, Mohlere V, Bynon JS. Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine +/-cisplatin combination. *Cancer Med.* 2019 July;8(7):3464-3470.doi:10.1002/cam4.2181.Epub 2019 May 17.
89. Al-Obaidi M, Hasbun R, Vigil KJ, Edwards AR, Chavez V, Hall DR, Dar WA, De Golovine A, Ostrosky-Zeichner L, Bynon JS, Nigo M. Seroprevalence of *Strongyloides stercoralis* and Evaluation of Universal Screening in Kidney Transplant Candidates: A Single-Center Experience in Houston (2012-2017). *Open forum Infect Dis.* 2019 July 1;6(7).pii:0fz172.doi:10.1093/ofid/ofz172.

BOOK CHAPTERS:

1. **Bynon** JS Jr., Hudson SL, Kohaut EC, Benfield MR, Waldo FB, Diethelm AG. Pediatric renal transplantation at the University of Alabama at Birmingham, 1968 to 1993. *Clinical Transplants.* 259-65, 1993.
2. Taylor RJ, **Bynon** JS, Stratta RJ. Kidney/pancreas transplantation: a review of the current status. *Urologic Clinics of North America.* 21(2):343-54, 1994 May.
3. **Bynon** JS Jr., Kenchtle SJ. Donor en bloc hepatectomy, pancreatectomy, and nephrectomy. *UNOS, Organ Procurement, Preservation and Distribution in Transplantation*, M.G. Phillips (Ed.) 2nd Edition. Chapter 12, 129-137, 1996.
4. Bynon JS Jr., Transplantation of the "marginal" liver allograft. *Avances en hepatologia clinica*, A.T. Delgadillo (Ed.) Chapter 4.4, 113-114, 2015

PRESENTATIONS:

1. "A Review of Living-Related Liver Transplantation in Children", Southern Pediatric Gut Club, Point, Clear, AL., July 1993.
2. "Pediatric Transplantation". 12th Annual Organ and Tissue Donation Transplant Seminar, Alabama Organ Center, Perdido Beach, AL. April 14, 1994.
3. "Referral of the Acute and Chronic Patient for Liver Transplantation", UAB Gastroenterology Update, , Birmingham, AL. April 15-16, 1994.
4. "Liver Transplantation", UAB Nephrology Grand Rounds, Birmingham, AL., December 13, 1994.
5. "Liver Transplantation" Surgical Society of the University of Alabama, 1995.
6. "Liver Transplantation", Case Managers Association of Alabama (Conference), Birmingham, AL., May 12, 1995.
7. "Pediatric Liver Transplantation", Alabama Chapter of American College of Surgeons (Conference), Point Clear, AL., May 13, 1995.

8. "The Buck Stops Here" (Contemporary Issues in Cost-Containment for Transplantation), International Transplant Nurse Society (Conference), Birmingham, AL., June 15, 1995.
9. "Update on Liver Transplantation", Alabama Organ Center Joint Meeting, Birmingham, AL., November 9, 1995.
10. "The Infamous Aspects of Liver Transplantation", Case Manager's Association Meeting (Conference), Jackson, MS. December 5, 1995.
11. "Liver Recovery and Transplantation", Alabama Organ Center, Pensacola, FL., May 2, 1996.
12. "Budd-Chiari Syndrome", UAB Grand Rounds, Birmingham, AL., September 28, 1996
13. "Hepatic Failure", UAB Clinical Nurse Specialists group, Birmingham, AL., October 21, 1996
14. "Review of University of Alabama at Birmingham's Liver Transplant Program", UAB Transplant Center Seminar, Birmingham, AL., November, 1996.
15. "Update on Liver Transplantation", Alabama Organ Center Medical Advisory Meeting, Birmingham, AL., November 21, 1996.
16. "Human Anatomy". Invited Speaker. Mountain Brook Elementary School, Career Development Series. 1996.
17. "Liver Transplant Evaluation", University of Tennessee, College of Medicine, Erlanger Medical Center, Grand Rounds, Chattanooga, TN., January 30, 1997.
18. "Liver Transplantation "Who Should be Transplanted?", East Alabama Medical Center, Physicians Conference, Opelika, AL., April 1, 1997.
19. "Liver Transplantation", Lanier Hospital, Physicians Group, Valley, AL., April 16, 1997.
20. "Cryotherapy for Hepatic Metastases", Alabama Chapter, American College of Surgeons (Conference), Perdido Beach, AL., May 9, 1997.
21. "Transplant Statistics and Future Directions for the Liver Transplant Program", UAB Hospital Managers Meeting, Birmingham, AL., July 30, 1997.
22. "Outcomes of Liver Transplantation", UAB Medical Forum Clinical Hepatology and Transplantation, Birmingham, AL., October 4, 1997.
23. "Patient Evaluation and Selection for Liver Transplantation", United Resource Network Transplant Conference for Payor Medical Directors, Orlando, FL., December 9, 1997.
24. "Organ Donor Awareness" UAB General Medicine Conference, Birmingham, AL. April 28, 1998.
25. "Liver Transplantation". Gulf Coast Liver Disease Support Group, USA Knollwood Hospital, Mobile, AL., July 23, 1998.

26. "Outcomes and Liver Transplantation", Transplant Journal Club, Medical College of Georgia, Augusta, GA., August 18, 1998.
27. "Fulminant Hepatic Failure: Managing A Crisis", United Resource Networks Seventh Annual National Clinical Conference (Innovations In Transplantation: Expanding Knowledge and Improving Outcomes", Minneapolis, MN., September 15, 1998.
28. "Indications for Intestinal Transplantation", UAB Grand Rounds, Birmingham, AL., October 3, 1998.
29. "Hepatitis C and Liver Transplantation". United Resource Network Presentation. Phoenix, Arizona, November 14, 1998.
30. "Hepatocellular Carcinoma", International Symposium of Hepatic, Biliary and Pancreatic Surgery, Mexico, March 8-10, 1999.
31. "Quality of Life After Liver Transplantation". International Symposium of Hepatic, Biliary and Pancreatic Surgery, Mexico, March 8-10, 1999
32. "Liver Transplant Program. How to start and make it work". International Symposium of Hepatic, Biliary and Pancreatic Surgery, Mexico, March 8-10, 1999.
33. "Fulminant Hepatic Failure: Diagnosis and Treatment". United Resource Networks, The Application of New Technologies Along the Continuum of Care conference. New York, New York, April 7-9, 1999. (Conference Director)
34. "Short and Long-Term Care of the Post-Abdominal Transplant Patient". United Resource Networks, The Application of New Technologies Along the Continuum of Care Conference. New York, New York, April 7-9, 1999. (Conference Director)
35. "Living-Related Donor Transplants". Cardiothoracic Surgery Service Line Staff. University of Alabama in Birmingham, August 2, 1999.
36. "Expanding the Donor Pool: Utilizing Live Donors for Abdominal Transplantation". United Resource Networks. San Francisco, California. November 10-12, 1999
37. "Portal Hypertension". University of Alabama at Birmingham. Presentation at Residents Basic Science Course. November 20, 1999
38. "Organ Transplantation". Invited Speaker. Mountain Brook Elementary School, Career Development Series. 1999.
39. "Split Liver and Living Related Transplantation". Grand Rounds, University of Alabama in Birmingham, March 25, 2000.
40. "Organ Donations". Invited Speaker. University of South Alabama Support Group Meeting, Mobile, AL. June 22, 2000.
41. "Organ and Tissue Donation". Invited Speaker. The Birmingham Chapter of Hadassah meeting. Birmingham, AL. November 19, 2000.

42. "Update on Liver Transplantation". Department of Medicine Grand Rounds. Gwinnett Health System. Lawrenceville, Georgia. May 24, 2001.
43. "Liver Transplantation", Transplant Center Forum, University of Alabama in Birmingham, May 10, 2001.
44. 10th Annual National Clinical Conference, Beyond the Horizon: Exploring Scientific Advances in Transplantation, United Resource Network. "Liver Transplantation: Organ Allocation Policy and Optimal Referral Timing". Minneapolis, MN., September 10-11, 2001.
45. "Long-Term Care of the Liver Transplant Patient". 4th Biennial Conference sponsored by UAB Liver Center. Birmingham, AL., September 27-28, 2001.
46. "Organ Donation". Invited Speaker. Fellowship Class of Canterbury Methodist Church. Birmingham, Alabama, 12/30/01
47. "Liver Transplantation For Viral Hepatitis B and C", Surgery Grand Rounds, University of Alabama in Birmingham, January 17, 2002.
48. "Living Donor Liver Transplantation". Instituto Nacional De Ciencias Medicas Y Nutricion, X International HPB Course, Mexico City. March 6-9, 2002.
49. "Liver Transplantation and HCC". Instituto Nacional De Ciencia Medicas Y Nutricion, X International HPB Course, Mexico City. March 6-9, 2002.
50. "Liver Transplantation. Results". Instituto Nacional De ciencia Medicas y Nutricion, X International HPB Course, Mexico City. March 6-9, 2002.
51. "An Overview of Liver Transplantation". Novartis Transplantation Training Course for CRAs, East Hanover, NJ, August 21-23, 2002.
52. "Intestinal Transplantation". Southeast Region Conference for Wound, Ostomy, and Continence Nursing annual conference. Birmingham, Alabama, September 8, 2002.
53. "Review of Liver Transplantation". Alabama Organ Center's annual Advisory Committee meeting, Birmingham, Alabama. November 7, 2002.
54. "Hepatic Transplantation". Transplantation Specialty Training for CRAs presented by Novartis. United Kingdom. December 4-6, 2002.
55. "Pediatric Renal Transplantation". Pediatric Grand Rounds lectureship at Driscoll Children's Hospital's. Corpus Christi, TX. December 20, 2002.
56. "Immunosuppression and Pediatric Renal and Liver Transplantation", Grand Rounds, The University of Texas Health Science Center, San Antonio, TX., Sponsored by Novartis, February 28, 2003.
57. "Radiofrequency Ablation of Liver Cancers", The Risk Appraisal forum (National group "Independent Life Brokerage Agencies). Birmingham, AL., April 25, 2003.
58. "Management of Hepatitis C Virus-Treatment Options, Psychosocial Issues and

- Retransplantation”, United Resource Networks 12th Annual National Clinical Conference. Minneapolis, MN. September 16, 2003.
59. “Hepatic Transplantation”, Novartis Transplantation CRA Course. London, England. September 18, 2003.
 60. “Liver Transplantation”, Fujisawa Site Visit. University of Alabama in Birmingham, Birmingham, AL. October 14, 2003.
 61. “Review of Liver Transplantation”, The Alabama Organ Center’s Annual Advisory Committee Meeting. Birmingham, AL. November 6, 2003
 62. “Hepatitis C: Treatment Options and Psychological Issues”, United Resource Networks The 5th Annual: Emerging Technologies and Innovative Approaches for Managing Patients With Complex Medical Conditions (A Medical Management Conference), New Orleans, LA., February 4-6, 2004.
 63. “Organ Transplantation”, Birmingham Estate Planning Council. Birmingham, AL. March 4, 2004.
 64. “Renal and Liver Failure Patients – Care During Transport”, Critical Care Transport Service. Birmingham, AL. May 26, 2004.
 65. “HCC”, Hematology/Oncology Fellows at UAB. Birmingham, AL. June 8, 2004.
 66. “Liver Transplantation at UAB”, sponsored by Roche. Presented to Transplant Division, Emory University, Atlanta, GA., November 10, 2004.
 67. “Overview of Liver Transplant Program at UAB”. The Alabama Organ Center’s annual Advisory Committee Meeting, Birmingham, AL. November 17, 2004.
 68. “Transplantation and Retranplantation for Patients with Hepatitis C”, United Resource Networks Audio Conference, Birmingham, Al. December 7, 2004.
 69. “Liver Transplantation in the Era of MELD”. 2005 Update in Liver Disease, sponsored by UAB Liver Center & Division of Gastroenterology/Hepatology, Birmingham, AL. September 15-16, 2005.
 70. “UAB Pediatric Liver Transplant Experience”. Presented at Pediatric Medical Grand Rounds, The Children’s Hospital, Birmingham, AL. February 2, 2006.
 71. “Future of Living Related Transplants in Adults and Children”. Blue Cross Blue Shield Association Audio conference. Birmingham, AL. February 23, 2006.
 72. “Liver Transplantation for the High-Risk Patient”. United Resource Networks Medical Management Conference – The 7th Annual: Emerging Technologies and Innovative Approaches for Managing Patients With Complex Medical Conditions. Miami Beach, FL. February 28-March 3, 2006.
 73. “Pediatric Transplantation”. Presented at The Children’s Hospital Nursing Retreat, Botanical Gardens, Birmingham, AL. March 30, 2006.

74. "New and Future Developments in Liver Transplantation". Presented at PM &R Grand Rounds, CPM Auditorium, Birmingham, AL. April 28, 2006.
75. "Postoperative Care". Children's Hospital Pediatric Professional Development Day. Bradley Lecture Center, The Children's Hospital, Birmingham, AL. May 5, 2006.
76. "Overview of Liver Transplantation". Presented to floor and nurse coordinators at University Hospital, Birmingham, AL. August 29, 2006.
77. "The Role of Liver Transplantation in the Management of Hepatocellular Carcinoma. Surgery Grand Rounds. Birmingham, AL. February 1, 2007.
78. "Current Update: Management of Solitary Hepatic Lesions". 2007 Conference of the Alabama Chapter of the American College of Surgeons, Birmingham, AL. April 12-14, 2007
79. "Surgical Management of Liver Tumors". 2007 Update in Hepatobiliary Disease. Birmingham, AL. September 21, 2007.
80. "An Overview of Abdominal Organ transplantation" OptumHealth's Course in Transplantation. San Antonio, TX. March 3, 2008
81. "Liver Transplantation: Patient Selection and Evaluation. Hospitalization to Discharge Care Issues" OptumHealth's Course in Transplantation. San Antonio, TX. March 3, 2008.
82. "Making The Case for Pre-emptive Transplant". OptumHealth's Teleconference. September 18, 2008.
83. "Treatment of Hepatocellular Carcinoma". Montgomery Cancer Center, Montgomery, AL., March 11, 2009.
84. "Kidney/Liver Transplantation and MELD Exceptions". Optum Health's Abdominal and Thoracic Expert Panel Meeting. , Chicago, IL. March 18, 2009.
85. "Transplantation of the High Risk Recipient". Flowers Hospital, Medical Group, Dothan, AL. May 11, 2009.
86. "Update in Liver Transplant". 2009 Update in Hepatobiliary Disease 7th Biennial Conference, Birmingham, AL. September 24-25, 2009.
87. "Patient Selection and Indicators for Liver Transplant – Nursing Role". Auburn University Nursing Students, October 27, 2009.
88. "Kidney Transplantation". Optum Health Pediatric Complex Condition Management Expert Panel Meeting. Chicago, IL. February 2, 2010.
89. "Liver Transplantation from the Point of View of the Surgeon". UAB School of Medicine, Anesthesiology Grand Rounds. June 14, 2010.
90. "Organ and Tissue Donation". Memorial Hermann Bridgeland Triathlon EXPO, Norris Conference Center, Houston, TX. August 6, 2011.

91. "Liver Transplant: An Overview of Indications and Outcomes". Surgery Grand Rounds, The University of Texas Medical School at Houston, Houston, TX. December 2, 2011.
92. "Advances in Immunosuppression and Outcomes". Inaugural Speaker, 2nd Annual AASLD Update: The Gulf Cost Gastroenterology Society, Houston, TX. December 3, 2011.
93. "Transplantation". Immunology Course Lecture, Department of Pathology and Laboratory Medicine, The University of Texas Medical School at Houston, Houston, TX. February 14, 2012.
94. "Cholangiocarcinoma: A Surgeons Perspective". Surgery Grand Rounds, The University of Texas Medical School at Houston, Houston, TX. July 19, 2012.
95. "Graft Vs. Host Disease in Liver Recipients". Texas Transplantation Society 2012 Annual Scientific Meeting, Galveston, TX. July 28, 2012.
96. "Early Post-Operative Complications in Liver Transplant". Transplant Symposium, Memorial Hermann Hospital-TMC/The University of Texas Medical School at Houston, Houston, TX. October 12 and November 2, 2012.
97. "Advances in Immunosuppression, Outcomes and Complications." 3rd Annual AASLD Highlights Conference, Hornberger Conference Center, Houston, TX. December 1, 2012.
98. "HCC Resection vs. Transplant". 2012-2013 UTHealth Oncology Seminar Series, The University of Texas Medical School at Houston, Houston, TX. December 13, 2012.
99. "Surgical Management of Portal Hypertension". Department of Surgery Grand Rounds, The University of Texas Medical School at Houston, Houston, TX. August 15, 2013.
100. "Advances in Immunosuppression, Outcomes and Complications". 4th Annual AASLD Highlight's Conference, Onstead Auditorium, Basic Sciences Research Building, Houston, TX. December 7, 2013.
101. "Liver Transplantation and/or Complex Liver Biliary Surgery". New Developments in Gastroenterology, Hepatology and Hepatic Surgery, Memorial Hermann Hospital, Memorial City, Houston, TX. February 15, 2014.
102. "Transplantation of the Marginal Hepatic Allograft". Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zuiran. Annual Course Department of Gastroenterology. Mexico City, July 2-4, 2015.
103. "History of Kidney Transplantation" Memorial Hermann Transplant Conference, Oct. 19, 2018.
104. "The use of less than whole livers for transplantation; A story of anatomy and innovation" Surgical Grand Rounds McGovern School of Medicine, 8/2/2018.
105. "Dental Considerations in Transplant Patients" Hinds Seminar Oral Surgery, McGovern School of Medicine, April 26, 2019.
106. "This little piggy went to market" Memorial Hermann Transplant Conference, Oct. 18, 2019.
107. "Have Graft Outcomes Improved for Pediatric Transplant Recipients Since the Implementation of the Kidney Allocation System", American Transplant Congress, Conecurrent

Session: Kidney: Pediatrics 1, Boston MA. June 2, 2019.

VIDEOS:

Video production, sponsored by UAB, "UAB Transplant Programs". Purpose: For use in negotiations by Managed Care Contracting and for prospective patient education, April 1996.

Video Production, sponsored by Fujisawa Pharmaceuticals Company. "Sharing the Experience". Purpose: Patient education for adult transplant patients, August 2001.

Video Production, Fujisawa Pharmaceuticals Company. Purpose: Patient Education for Pediatric transplant patients, November 2001.

OTHER:

Liver Transplant Program Business Plan

Purpose: Developed to strategically position the University of Alabama at Birmingham Health System's Liver Transplant Program in the healthcare market, August 1996.

Liver Transplant Patient Protocol Book

Purpose: To educate house staff and standardize patient care for adult and pediatric patients, 1994, 1999.

Liver Transplant Program PIN Orders

Purpose: To standardize patient care for University of Alabama at Birmingham transplant program. (Used by nurses/residents, nurse practitioners)

Pediatric March 1994

Adult July 1995

Critical Pathway Adult Liver Transplant Program

Purpose: To promote greater efficiency in postoperative care, Developed with Debbie Ragan, RN, Director, Transplant and General Surgical Nursing. For nurses/insurance companies. 1999-2000.